Weekly Analyst Ratings Updates for Legend Biotech (LEGN)


Several brokerages have updated their stock price recommendations and targets. Legend Biotech (NASDAQ: LEGN) over the past few weeks:

  • 05/10/2022 – Legend Biotech has been upgraded by Zacks Investment Research analysts from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. She is engaged in the discovery and development of novel cell therapies for oncology and other indications. The Company’s lead product is LCAR-B38M/JNJ-4528, which is in clinical phase. Legend Biotech Corporation is based in the Cayman Islands. “
  • 04/05/2022 – Legend Biotech has been downgraded by analysts at Zacks Investment Research from a “Hold” rating to a “Sell” rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. She is engaged in the discovery and development of novel cell therapies for oncology and other indications. The Company’s lead product is LCAR-B38M/JNJ-4528, which is in clinical phase. Legend Biotech Corporation is based in the Cayman Islands. “
  • 04/28/2022 – Legend Biotech has been upgraded by Zacks Investment Research analysts from a ‘Sell’ rating to a ‘Hold’ rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. She is engaged in the discovery and development of novel cell therapies for oncology and other indications. The Company’s lead product is LCAR-B38M/JNJ-4528, which is in clinical phase. Legend Biotech Corporation is based in the Cayman Islands. “
  • 04/20/2022 – Legend Biotech has been upgraded by Zacks Investment Research analysts from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. She is engaged in the discovery and development of novel cell therapies for oncology and other indications. The Company’s lead product is LCAR-B38M/JNJ-4528, which is in clinical phase. Legend Biotech Corporation is based in the Cayman Islands. “
  • 04/14/2022 – Legend Biotech has been upgraded by Zacks Investment Research analysts from a “Sell” rating to a “Hold” rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. She is engaged in the discovery and development of novel cell therapies for oncology and other indications. The Company’s lead product is LCAR-B38M/JNJ-4528, which is in clinical phase. Legend Biotech Corporation is based in the Cayman Islands. “
  • 03/29/2022 – Legend Biotech has been upgraded by Zacks Investment Research analysts from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. She is engaged in the discovery and development of novel cell therapies for oncology and other indications. The Company’s lead product is LCAR-B38M/JNJ-4528, which is in clinical phase. Legend Biotech Corporation is based in the Cayman Islands. “
  • 03/23/2022 – Legend Biotech has been downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. She is engaged in the discovery and development of novel cell therapies for oncology and other indications. The Company’s lead product is LCAR-B38M/JNJ-4528, which is in clinical phase. Legend Biotech Corporation is based in the Cayman Islands. “
  • 03/16/2022 – Legend Biotech has been upgraded by analysts at Zacks Investment Research from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. She is engaged in the discovery and development of novel cell therapies for oncology and other indications. The Company’s lead product is LCAR-B38M/JNJ-4528, which is in clinical phase. Legend Biotech Corporation is based in the Cayman Islands. “
  • 03/15/2022 – Legend Biotech is now covered by Barclays PLC analysts. They set an “overweight” rating and a price target of $53.00 on the stock.

Shares of Legend Biotech rose $1.63 during Tuesday’s trading, hitting $35.17. The stock had a trading volume of 646,901 shares, compared to an average trading volume of 732,378. The stock has a market capitalization of $5.42 billion, a price-earnings ratio of -25.86 and a beta of -0.10. Legend Biotech Co. has a 12 month minimum of $28.36 and a 12 month maximum of $58.00. The company’s 50-day moving average price is $38.31. The company has a debt ratio of 0.26, a quick ratio of 3.38 and a current ratio of 3.39.

Legend Biotech (NASDAQ:LEGN – Get Rating) last released its quarterly results on Friday, March 18. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). The company had revenue of $39.00 million in the quarter, versus a consensus estimate of $13.23 million. Legend Biotech had a negative return on equity of 131.45% and a negative net margin of 429.40%. On average, sell-side analysts expect Legend Biotech Co. to post -1.63 earnings per share for the current fiscal year.

A number of large investors have recently changed their positions in LEGN. Morgan Stanley increased its position in Legend Biotech by 21.4% in the second quarter. Morgan Stanley now owns 57,707 shares of the company worth $2,369,000 after acquiring 10,161 additional shares in the last quarter. Bank of America Corp DE increased its position in Legend Biotech by 39.1% in the second quarter. Bank of America Corp DE now owns 14,124 shares of the company valued at $579,000 after purchasing an additional 3,970 shares during the period. Deutsche Bank AG increased its position in Legend Biotech by 1,268.4% in the third quarter. Deutsche Bank AG now owns 104,955 shares of the company valued at $5,307,000 after purchasing an additional 97,285 shares during the period. BlackRock Inc. increased its position in Legend Biotech by 4.4% during the third quarter. BlackRock Inc. now owns 837,927 shares of the company valued at $42,365,000 after purchasing an additional 35,330 shares during the period. Finally, Alliancebernstein LP increased its position in Legend Biotech by 5.3% during the third quarter. Alliancebernstein LP now owns 1,998,150 shares of the company valued at $101,026,000 after purchasing an additional 101,167 shares during the period.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China and the international. Its lead product candidate, LCAR-B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a treatment comparison to standard triple therapy in revlimid-refractory multiple myeloma.

Featured articles



Get news and reviews for Legend Biotech Co Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Legend Biotech Co and related companies with MarketBeat.com’s free daily email newsletter.

About Catriona

Check Also

Why major streamers are reassessing the way they do business amid recession fears | Features

The past few months have not been easy for streamers. The specter of a recession …